These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 33085834)
1. Unique Considerations for the Management of Gout in the Hmong Population: Examining Tertiary Encounters at a Large Regional Health Care System. Lerman A; Gertner E; DeFor TA; Brown M; Desai J Arthritis Care Res (Hoboken); 2022 Mar; 74(3):461-467. PubMed ID: 33085834 [TBL] [Abstract][Full Text] [Related]
2. Gout in the Hmong in the United States. Wahedduddin S; Singh JA; Culhane-Pera KA; Gertner E J Clin Rheumatol; 2010 Sep; 16(6):262-6. PubMed ID: 20808166 [TBL] [Abstract][Full Text] [Related]
3. Gout prevalence in the Hmong: a prime example of health disparity and the role of community-based genetic research. Roman YM; Lor K; Xiong T; Culhane-Pera K; Straka RJ Per Med; 2021 May; 18(3):311-327. PubMed ID: 33787318 [TBL] [Abstract][Full Text] [Related]
4. High prevalence of gouty arthritis among the Hmong population in Minnesota. Portis AJ; Laliberte M; Tatman P; Moua M; Culhane-Pera K; Maalouf NM; Sakhaee K Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1386-91. PubMed ID: 20506247 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Juge PA; Truchetet ME; Pillebout E; Ottaviani S; Vigneau C; Loustau C; Cornec D; Pascart T; Snanoudj R; Bailly F; Cornec-Le Gall E; Schaeverbeke T; Saraux A; Dieudé P; Flipo RM; Richette P; Lioté F; Bardin T; Chalès G; Ea HK Joint Bone Spine; 2017 Oct; 84(5):595-598. PubMed ID: 27825577 [TBL] [Abstract][Full Text] [Related]
6. Gout in women: differences in risk factors in young and older women. Kumar S; Gupta R; Suppiah R N Z Med J; 2012 Oct; 125(1363):39-45. PubMed ID: 23159900 [TBL] [Abstract][Full Text] [Related]
7. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. Primatesta P; Plana E; Rothenbacher D BMC Musculoskelet Disord; 2011 May; 12():103. PubMed ID: 21599917 [TBL] [Abstract][Full Text] [Related]
8. Burden and management of gout in a multi-ethnic Asian cohort. Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246 [TBL] [Abstract][Full Text] [Related]
9. Facilitating equitable prevention and management of gout for Māori in Northland, New Zealand, through a collaborative primary care approach. Lawrence A; Scott S; Saparelli F; Greville G; Miller A; Taylor A; Gow P J Prim Health Care; 2019 Jul; 11(2):117-127. PubMed ID: 32171354 [TBL] [Abstract][Full Text] [Related]
10. African American patients with gout: efficacy and safety of febuxostat vs allopurinol. Wells AF; MacDonald PA; Chefo S; Jackson RL BMC Musculoskelet Disord; 2012 Feb; 13():15. PubMed ID: 22316106 [TBL] [Abstract][Full Text] [Related]
11. Engaging in Culturally Informed Nursing Care With Hmong Children and Their Families. Xiong S; Degroote N; Byington H; Harder J; Kaminski K; Haglund K J Pediatr Nurs; 2016; 31(1):102-6. PubMed ID: 26413994 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study. Saag KG; Becker MA; Whelton A; Hunt B; Castillo M; Kisfalvi K; Gunawardhana L Arthritis Rheumatol; 2019 Jan; 71(1):143-153. PubMed ID: 30073793 [TBL] [Abstract][Full Text] [Related]
13. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Bakris GL; Doghramji PP; Keenan RT; Silber SH Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074 [TBL] [Abstract][Full Text] [Related]
14. Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: A primary care retrospective cohort study. Janssens HJ; Arts PG; Schalk BW; Biermans MC Joint Bone Spine; 2017 Jan; 84(1):59-64. PubMed ID: 27236260 [TBL] [Abstract][Full Text] [Related]
15. Prevention of comorbidity and acute attack of gout by uric acid lowering therapy. Joo K; Kwon SR; Lim MJ; Jung KH; Joo H; Park W J Korean Med Sci; 2014 May; 29(5):657-61. PubMed ID: 24851021 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Keenan RT; O'Brien WR; Lee KH; Crittenden DB; Fisher MC; Goldfarb DS; Krasnokutsky S; Oh C; Pillinger MH Am J Med; 2011 Feb; 124(2):155-63. PubMed ID: 21295195 [TBL] [Abstract][Full Text] [Related]
17. Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy. Drivelegka P; Sigurdardottir V; Svärd A; Jacobsson LTH; Dehlin M Arthritis Res Ther; 2018 Jun; 20(1):108. PubMed ID: 29855389 [TBL] [Abstract][Full Text] [Related]
18. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028 [TBL] [Abstract][Full Text] [Related]
19. A prospective study of acute inpatient gout diagnoses and management in a tertiary hospital: the determinants and outcome of a rheumatology consultation. Teichtahl AJ; Clemens L; Nikpour M; Romas E Intern Med J; 2014 Nov; 44(11):1095-9. PubMed ID: 25069385 [TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Singh JA; Akhras KS; Shiozawa A Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]